JP7520719B2 - 生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター - Google Patents

生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター Download PDF

Info

Publication number
JP7520719B2
JP7520719B2 JP2020551263A JP2020551263A JP7520719B2 JP 7520719 B2 JP7520719 B2 JP 7520719B2 JP 2020551263 A JP2020551263 A JP 2020551263A JP 2020551263 A JP2020551263 A JP 2020551263A JP 7520719 B2 JP7520719 B2 JP 7520719B2
Authority
JP
Japan
Prior art keywords
rna
origin
seq
replication
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020551263A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518150A (ja
JP2021518150A5 (enExample
Inventor
エー． ウィリアムズ，ジェームズ
Original Assignee
アルデブロン，エル．エル．シー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルデブロン，エル．エル．シー． filed Critical アルデブロン，エル．エル．シー．
Publication of JP2021518150A publication Critical patent/JP2021518150A/ja
Publication of JP2021518150A5 publication Critical patent/JP2021518150A5/ja
Priority to JP2024110895A priority Critical patent/JP7860174B2/ja
Application granted granted Critical
Publication of JP7520719B2 publication Critical patent/JP7520719B2/ja
Priority to JP2026075524A priority patent/JP2026116424A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/101—Plasmid DNA for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/55—Vectors comprising a special origin of replication system from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185—Escherichia
    • C12R2001/19—Escherichia coli

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Carbon And Carbon Compounds (AREA)
JP2020551263A 2018-03-21 2019-03-20 生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター Active JP7520719B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024110895A JP7860174B2 (ja) 2018-03-21 2024-07-10 生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター
JP2026075524A JP2026116424A (ja) 2018-03-21 2026-04-28 生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862645892P 2018-03-21 2018-03-21
US62/645,892 2018-03-21
PCT/US2019/023209 WO2019183248A1 (en) 2018-03-21 2019-03-20 Viral and non-viral nanoplasmid vectors with improved production

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024110895A Division JP7860174B2 (ja) 2018-03-21 2024-07-10 生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター

Publications (3)

Publication Number Publication Date
JP2021518150A JP2021518150A (ja) 2021-08-02
JP2021518150A5 JP2021518150A5 (enExample) 2022-03-29
JP7520719B2 true JP7520719B2 (ja) 2024-07-23

Family

ID=66001381

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020551263A Active JP7520719B2 (ja) 2018-03-21 2019-03-20 生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター
JP2024110895A Active JP7860174B2 (ja) 2018-03-21 2024-07-10 生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター
JP2026075524A Pending JP2026116424A (ja) 2018-03-21 2026-04-28 生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024110895A Active JP7860174B2 (ja) 2018-03-21 2024-07-10 生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター
JP2026075524A Pending JP2026116424A (ja) 2018-03-21 2026-04-28 生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター

Country Status (13)

Country Link
US (1) US12600984B2 (enExample)
EP (2) EP4151735A1 (enExample)
JP (3) JP7520719B2 (enExample)
KR (1) KR20210016330A (enExample)
CN (2) CN112154208B (enExample)
AU (2) AU2019240068B2 (enExample)
CA (1) CA3093346A1 (enExample)
DK (1) DK3768846T5 (enExample)
ES (1) ES2950736T3 (enExample)
FI (1) FI3768846T3 (enExample)
LT (1) LT3768846T (enExample)
SG (1) SG11202009009UA (enExample)
WO (1) WO2019183248A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019240068B2 (en) * 2018-03-21 2025-03-13 Aldevron, L.L.C. Viral and non-viral nanoplasmid vectors with improved production
EP3898993A1 (en) * 2018-12-20 2021-10-27 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use
WO2021055760A1 (en) 2019-09-18 2021-03-25 Intergalactic Therapeutics, Inc. Synthetic dna vectors and methods of use
KR20220153606A (ko) * 2020-03-11 2022-11-18 네이쳐 테크놀로지 코포레이션 박테리아 숙주 균주
CA3201499A1 (en) 2020-11-13 2022-05-19 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
US20230055381A1 (en) 2021-06-25 2023-02-23 Oxford Biomedica Solutions Llc Adeno-associated virus packaging systems
JP2024531910A (ja) 2021-08-04 2024-09-03 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト Ｌａｔ活性化キメラ抗原受容体ｔ細胞及びその使用方法
CN114045305B (zh) * 2021-10-15 2023-03-24 深圳市深研生物科技有限公司 多转座子系统
US20230323395A1 (en) 2021-12-15 2023-10-12 Homology Medicines, Inc. Methods and compositions for the production of adeno-associated virus
WO2023172514A1 (en) 2022-03-07 2023-09-14 Catamaran Bio, Inc. Engineered immune cell therapeutics targeted to her2 and methods of use thereof
CN118742645B (zh) * 2022-06-13 2025-07-15 南京金斯瑞生物科技有限公司 一种可提高无筛选标签质粒制备效率的野生型-突变体π蛋白切换表达系统
JP2025525583A (ja) 2022-07-19 2025-08-05 ランパート バイオサイエンス インコーポレイテッド 非免疫原性環状非ウイルス性ｄｎａベクター
CN117305339B (zh) * 2023-11-30 2024-02-06 苏州左旋星生物科技有限公司 优化大肠杆菌基因编辑的载体及其应用
CN122497758A (zh) 2024-01-25 2026-07-31 阿尔德夫隆有限责任公司 具有改进的生产性能的病毒和非病毒纳米质粒载体
WO2025231315A2 (en) 2024-05-03 2025-11-06 Aldevron, L.L.C. Bacterial host strains
WO2026076187A1 (en) * 2024-10-03 2026-04-09 Aldevron, L.L.C. Compositions and methods for microbial production of antibiotic-free closed-ended linear dna

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002013602A1 (fr) 2000-08-16 2002-02-21 Kansai Technology Licensing Organization Co., Ltd. Mammifere transgenique non humain et procede de realisation de ce dernier, modele de maladie animale et procede de clarification de la fonction genique
US20040072326A1 (en) 2000-08-30 2004-04-15 Alfonso Cayota Guzicovsky Methods for preparing human thrombopoietin polypeptides by mammalian cell cultures
WO2005003342A1 (ja) 2003-07-08 2005-01-13 Japan Science And Technology Agency メチル化を利用したトランスジェニック生物を作製する方法およびシステム
WO2007004642A1 (ja) 2005-07-05 2007-01-11 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 改変トランスポゾンベクター及びその利用方法
WO2014035457A1 (en) 2012-08-29 2014-03-06 Nature Technology Corporation Dna plasmids with improved expression
WO2014077863A1 (en) 2012-11-19 2014-05-22 Nature Technology Corporation Replicative minicircle vectors with improved expression
JP2016521553A (ja) 2013-06-06 2016-07-25 ノバルティス アーゲー インフルエンザウイルス再集合

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04197185A (ja) * 1990-11-28 1992-07-16 Mitsui Toatsu Chem Inc 酵母発現ベクター及びこれを用いた誘導的発現
GB9506051D0 (en) 1995-03-24 1995-05-10 Univ Singapore Gene expression
US7279313B2 (en) 1995-09-15 2007-10-09 Centelion Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
FR2738842B1 (fr) 1995-09-15 1997-10-31 Rhone Poulenc Rorer Sa Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique
US5922583A (en) 1995-10-17 1999-07-13 Biostar Inc. Methods for production of recombinant plasmids
US6709844B1 (en) * 2000-11-16 2004-03-23 Mannkind Corporation Avoidance of undesirable replication intermediates in plasmid propagation
FR2821855B1 (fr) 2001-03-09 2004-04-02 Cayla Genes synthetiques et plasmides bacteriens depourvus de cpg
CA2794446C (en) * 2001-04-04 2015-09-08 Genencor International, Inc. Uncoupled productive and catabolic host cell pathways
KR20050026384A (ko) * 2002-04-26 2005-03-15 내셔날 인스티튜트 오브 어드밴스드 인더스트리얼 사이언스 앤드 테크놀로지 ＲＮＡｉ효과를 가지는 스템 루프 형 ＲＮＡ 분자 발현 시스템
GB0327056D0 (en) 2003-11-20 2003-12-24 Cobra Biolog Ltd Plasmid maintenance
EP1781800B1 (en) 2004-08-19 2013-06-19 Nature Technology Corp. Process for plasmid dna fermentation
EP2169072A1 (en) * 2004-08-23 2010-03-31 Alnylam Pharmaceuticals, Inc Multiple RNA polymerase III promoter expression constructs
TWI311152B (en) 2004-09-17 2009-06-21 Boehringer Ingelheim Rcv Gmbh & Co K Host-vector system for antibiotic-free cole1 plasmid propagation
EP1844142B1 (en) 2005-01-20 2015-08-12 Nature Technology Corporation Vectors and methods for genetic immunization
EP2160459A2 (en) 2007-05-23 2010-03-10 Nature Technology Corp. Improved e. coli plasmid dna production
AU2008262478B9 (en) 2007-05-29 2014-06-19 Aldevron, L.L.C. Vectors and methods for genetic immunization
US20110131668A1 (en) * 2007-08-14 2011-06-02 Commonwealth Scientific And Industrial Research Organisation Improved gene silencing methods
US9045759B2 (en) 2009-01-21 2015-06-02 James Arthur Williams DNA plasmids with improved copy number
US9012226B2 (en) 2009-03-13 2015-04-21 Nature Technology Corporation Bacterial strains with improved plasmid stability
US9506082B2 (en) 2010-04-12 2016-11-29 Nature Technology Corporation Eukaryotic expression vectors resistant to transgene silencing
HK1202578A1 (en) * 2011-12-07 2015-10-02 Ichnos Sciences SA Expression cassette
WO2017025447A1 (en) 2015-08-10 2017-02-16 Curevac Ag Method of increasing the replication of a circular dna molecule
WO2017066579A1 (en) 2015-10-14 2017-04-20 Audentes Therapeutics, Inc. Nucleic acid molecules containing spacers and methods of use thereof
AU2019240068B2 (en) 2018-03-21 2025-03-13 Aldevron, L.L.C. Viral and non-viral nanoplasmid vectors with improved production
EP3898993A1 (en) * 2018-12-20 2021-10-27 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002013602A1 (fr) 2000-08-16 2002-02-21 Kansai Technology Licensing Organization Co., Ltd. Mammifere transgenique non humain et procede de realisation de ce dernier, modele de maladie animale et procede de clarification de la fonction genique
US20040072326A1 (en) 2000-08-30 2004-04-15 Alfonso Cayota Guzicovsky Methods for preparing human thrombopoietin polypeptides by mammalian cell cultures
WO2005003342A1 (ja) 2003-07-08 2005-01-13 Japan Science And Technology Agency メチル化を利用したトランスジェニック生物を作製する方法およびシステム
WO2007004642A1 (ja) 2005-07-05 2007-01-11 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 改変トランスポゾンベクター及びその利用方法
WO2014035457A1 (en) 2012-08-29 2014-03-06 Nature Technology Corporation Dna plasmids with improved expression
WO2014077863A1 (en) 2012-11-19 2014-05-22 Nature Technology Corporation Replicative minicircle vectors with improved expression
JP2016521553A (ja) 2013-06-06 2016-07-25 ノバルティス アーゲー インフルエンザウイルス再集合

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Carnes A et al，Production of a Nanoplasmid with a large gene insert using the HyperGRO fermentation process，Engineering Conferences International ECI Digital Archives VACCINE TECHNOLOGY VI，2016年
Lu J et al.，A 5 Noncoding Exon Containing Engineered Intron Enhances Transgene Expression from Recombinant AAV Vectors in vivo，HUMAN GENE THERAPY，2016年，28(1)，p125-134, Supplemetary FigureS2

Also Published As

Publication number Publication date
US20210010021A1 (en) 2021-01-14
AU2019240068A1 (en) 2020-10-01
JP2021518150A (ja) 2021-08-02
CN120249340A (zh) 2025-07-04
DK3768846T3 (da) 2023-07-24
CA3093346A1 (en) 2019-09-29
EP3768846B1 (en) 2023-06-21
DK3768846T5 (da) 2024-08-19
EP4151735A1 (en) 2023-03-22
JP7860174B2 (ja) 2026-05-15
AU2025203312A1 (en) 2025-05-29
SG11202009009UA (en) 2020-10-29
KR20210016330A (ko) 2021-02-15
LT3768846T (lt) 2023-08-10
US12600984B2 (en) 2026-04-14
JP2024138410A (ja) 2024-10-08
ES2950736T3 (es) 2023-10-13
EP3768846A1 (en) 2021-01-27
AU2019240068B2 (en) 2025-03-13
FI3768846T3 (fi) 2023-06-30
WO2019183248A1 (en) 2019-09-26
JP2026116424A (ja) 2026-07-09
CN112154208A (zh) 2020-12-29
CN112154208B (zh) 2025-04-15

Similar Documents

Publication Publication Date Title
JP7860174B2 (ja) 生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター
US12215335B2 (en) Non-integrating DNA vectors for the genetic modification of cells
US10167478B2 (en) Replicative minicircle vectors with improved expression
JP7833134B2 (ja) 細菌宿主株
EP2890404A1 (en) Dna plasmids with improved expression
WO2019057774A1 (en) NON-INTEGRATING DNA VECTORS FOR THE GENETIC MODIFICATION OF CELLS
WO2025160245A1 (en) Viral and non-viral nanoplasmid vectors with improved production
HK40129088A (en) Production of improved viral and non-viral nanoplasmid vectors
WO2025231315A2 (en) Bacterial host strains
HK40031637B (en) Non-integrating dna vectors for the genetic modification of cells
HK40031637A (en) Non-integrating dna vectors for the genetic modification of cells

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20211110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220318

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240109

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20240119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240408

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240611

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240710

R150 Certificate of patent or registration of utility model

Ref document number: 7520719

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150